Design Therapeutics, Inc. (DSGN) Tops Q4 EPS by 6c

Design Therapeutics, Inc. (NASDAQ: DSGN) reported Q4 EPS of ($0.27), $0.06 better than the analyst estimate of ($0.33).

For earnings history and earnings-related data on Design Therapeutics, Inc. (DSGN) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• UBS Upgrades Pagegroup Plc. (PAGE:LN) (MPGPY) to Buy
• Syensqo SA (SYENS:BB) PT Raised to EUR100 at JPMorgan